Last Updated : May 10, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort descending | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Vraylar | cariprazine | Schizophrenia | Active | |||
| Breyanzi | lisocabtagene maraleucel | Relapsed or refractory large B-cell lymphoma | Received | |||
| Rybrevant | amivantamab | Locally advanced or metastatic non-small cell lung cancer (NSCLC) | Pending | |||
| Ryaltris | olopatadine hydrochloride and mometasone | Seasonal allergic rhinitis | Pending | |||
| TBC | avapritinib | Advanced Systemic Mastocytosis | Active | |||
| Keytruda | pembrolizumab | Gastric or gastroesophageal junction adenocarcinoma | Active | |||
| Forxiga | Dapagliflozin | Diabetes mellitus, type 2 | Do not list | Complete | ||
| Jinarc | Tolvaptan | Autosomal dominant polycystic kidney disease | Do not list | Complete | ||
| Juxtapid | Lomitapide | Hypercholesterolemia, homozygous familial | Do not list | Complete | ||
| Vimizim | Elosulfase alfa | Mucopolysaccharidosis IVA (Morquio A syndrome) | Do not list | Complete |
Last Updated : May 10, 2024